Content deleted Content added
m background to early clinical trial of Irosustat Tags: nowiki added Visual edit |
m background to clinical trials |
||
Line 55:
}}
'''Irosustat''' ({{abbrlink|INN|International Nonproprietary Name}}, {{abbrlink|USAN|United States Adopted Name}}; developmental code names '''STX-64''', '''667-coumate''', '''BN-83495'''; also known as '''oristusane''') is an [[oral administration|orally active]], [[irreversible inhibitor|irreversible]], [[nonsteroidal]] [[enzyme inhibitor|inhibitor]] of [[steroid sulfatase]] (STS) that was under development by [[Ipsen]] for the treatment of [[hormone-sensitive cancer]]s such as [[breast cancer]], [[prostate cancer]], and [[endometrial cancer]] but has not yet been marketed.<ref name="AdisInsight">http://adisinsight.springer.com/drugs/800020388</ref><ref name="pmid21342037">{{cite journal | vauthors = Palmieri C, Januszewski A, Stanway S, Coombes RC | title = Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer | journal = Expert Rev Anticancer Ther | volume = 11 | issue = 2 | pages = 179–83 | year = 2011 | pmid = 21342037 | doi = 10.1586/era.10.201 | url = }}</ref> The drug was designed and synthesized by the
In 2004 Sterix Ltd was acquired by Ipsen and the drug continued in development through formal academic-industry partnerships by Ipsen with the University of Bath and Imperial College. The drug reached [[Phases of clinical research#Phase II|phase II]] [[clinical trial]]s in hormone-dependent breast cancer and endometrial cancer prior to the discontinuation of its initial development as a monotherapy by Ipsen.<ref name="AdisInsight" /><ref name="AvendanoMenendez2015">{{cite book|author1=Carmen Avendano|author2=J. Carlos Menendez|title=Medicinal Chemistry of Anticancer Drugs|url=https://books.google.com/books?id=VEibBwAAQBAJ&pg=PA105|date=11 June 2015|publisher=Elsevier Science|isbn=978-0-444-62667-7|pages=105–}}</ref> It also reached a phase I trial in the USA for prostate cancer. However, the development of Irosustat has continued with clinical trials designed to explore its activity in early breast cancer and also in combination with an aromatase inhibitor. The results of these trials were published in 2017 and showed evidence of clinical benefit in patients.
| |||